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BMI

:   body mass index

CDKN1A

:   cyclin‐dependent kinase inhibitor 1A

GWAS

:   genome‐wide association studies

HSD17B13

:   hydroxysteroid 17‐beta dehydrogenase 13

IL

:   interleukin

IRAK

:   interleukin receptor associated kinase

MPO

:   myeloperoxidase

NAFLD

:   nonalcoholic fatty liver disease

NASH

:   nonalcoholic steatohepatitis

ORM1

:   orosomucoid 1

PNPLA3

:   patatin‐like phospholipase domain‐containing 3

SLAM

:   signaling lymphocytic activation molecule

T2DM

:   type 2 diabetes mellitus

TM6SF2

:   transmembrane 6 superfamily member 2

TNF‐α

:   tumor necrosis factor α

and WES

:   whole‐exome sequencing

Introduction {#hep41227-sec-0001}
============

NAFLD is a significant and increasing cause of morbidity and mortality worldwide, with global prevalence estimated at 25%.[1](#hep41227-bib-0001){ref-type="ref"} NAFLD consists of a spectrum of histology, ranging from benign liver fat accumulation to NASH, characterized by steatosis, necroinflammation, and fibrosis.[2](#hep41227-bib-0002){ref-type="ref"} NASH increases fibrosis progression risk, and advanced fibrosis predisposes to poor outcomes including decompensated cirrhosis, liver transplantation, and liver cancer.[2](#hep41227-bib-0002){ref-type="ref"} Several clinical factors (diabetes mellitus, obesity, male gender, and older age) are associated with hepatic fibrosis risk.[3](#hep41227-bib-0003){ref-type="ref"} However, not all NAFLD patients with risk factors develop advanced liver disease, suggesting a genetic contribution.[4](#hep41227-bib-0004){ref-type="ref"}, [5](#hep41227-bib-0005){ref-type="ref"} Genome‐wide association studies (GWAS) have reproducibly identified patatin‐like phospholipase domain‐containing 3 (*PNPLA3*) I148M as associated with NAFLD susceptibility and severity.[6](#hep41227-bib-0006){ref-type="ref"}, [7](#hep41227-bib-0007){ref-type="ref"}, [8](#hep41227-bib-0008){ref-type="ref"}, [9](#hep41227-bib-0009){ref-type="ref"} Although several additional genes have been implicated, including hydroxysteroid 17‐beta dehydrogenase 13 (*HSD17B13*) most recently,[10](#hep41227-bib-0010){ref-type="ref"} currently the only other independently reproducible association is with transmembrane 6 superfamily member 2 (*TM6SF2*),[8](#hep41227-bib-0008){ref-type="ref"}, [9](#hep41227-bib-0009){ref-type="ref"}, [11](#hep41227-bib-0011){ref-type="ref"} and few signals have been tracked to causal variants.

In contrast to GWAS, next‐generation sequencing interrogates rare variation and can often directly pinpoint causal variants including for complex diseases.[12](#hep41227-bib-0012){ref-type="ref"}, [13](#hep41227-bib-0013){ref-type="ref"} Understanding the full spectrum of NAFLD genetic variation predisposing to or protecting from advanced fibrosis may facilitate biomarker discovery or assist with novel treatment development. We used whole‐exome sequencing (WES) to examine the entire coding portion of the genome to identify potential causal variants for NAFLD fibrosis progression and protection. To accurately define different risk categories within the NAFLD spectrum, we used gold standard liver biopsy for NAFLD fibrosis staging and common clinical measurements related to NASH and advanced fibrosis. We sampled NAFLD phenotypic distribution extremes to enrich for selection of rare causal variants with potentially larger effect sizes.[14](#hep41227-bib-0014){ref-type="ref"} We defined two extreme NAFLD fibrosis phenotypes: "protective" and "progressor." We hypothesized that protective patients (i.e., those without advanced fibrosis despite being high risk \[older, obese, and diabetic\]) might harbor genetic variants that protect them from fibrosis progression, whereas progressor patients (i.e., those with advanced fibrosis despite lacking this clinical risk profile) might carry genetic variants enhancing their fibrosis vulnerability. Here we report a comprehensive WES study that investigates genetic variation underlying NAFLD fibrosis risk and progression.

Materials and Methods {#hep41227-sec-0002}
=====================

Patient Selection {#hep41227-sec-0003}
-----------------

We selected two cohorts of NAFLD patients from the Duke University Health System NAFLD Biorepository using an extreme phenotype design.[14](#hep41227-bib-0014){ref-type="ref"} The NAFLD Biorepository, details of which have been published previously, contains specimens and clinical data from NAFLD patients who underwent diagnostic liver biopsy to grade and stage NAFLD severity as standard of care.[15](#hep41227-bib-0015){ref-type="ref"} The Biorepository has the Duke Institutional Review Board\'s approval, and patients consented to genomic analyses.

We defined two extreme phenotypes of NAFLD: protective and progressor, based on the development of advanced liver fibrosis (fibrosis stage, F3‐F4). The protective phenotype included NAFLD patients expected to have significant liver injury and fibrosis based on clinical risk factors (age \>50 years, body mass index \[BMI\] ≥30 kg/m^2^, and type 2 diabetes mellitus \[T2DM\]) but with no or little fibrosis on liver biopsy (fibrosis stage, F0‐F1). At the other extreme, the progressor phenotype included NAFLD patients expected to have little fibrosis based on a lack of clinical risk factors (age \<55 years, BMI \<35 kg/m^2^, no T2DM), but biopsy showed advanced liver fibrosis or cirrhosis.

Final analyses included Caucasian individuals, the majority of both NAFLD cohorts. We compared the two extreme NAFLD phenotypes as well as each extreme phenotype to previously sequenced Caucasian population controls from unrelated Duke University studies with available consent for use.

Sequencing and Quality Control {#hep41227-sec-0004}
------------------------------

WES was performed on 103 NAFLD patients with available stored genomic DNA. Standard protocols and Illumina HiSeq platforms were used to sequence NAFLD patients and population controls (Supporting Information). Following quality control, 82 Caucasian NAFLD samples (54 protective, 28 progressor) and 4455 Caucasian population controls were available for analysis.

Data Analysis and Association Testing {#hep41227-sec-0005}
-------------------------------------

We performed downstream statistical analyses using in‐house pipeline ATAV version 5.8 software (<https://github.com/igm-team/atav/>).[13](#hep41227-bib-0013){ref-type="ref"} Three primary comparisons were conducted: (1) NAFLD progressor versus NAFLD protective; (2) NAFLD protective versus population controls; and (3) NAFLD progressor versus population controls. For each comparison, we performed single‐variant (Fisher\'s exact test) and gene‐based collapsing analyses (progressor versus protective λ = 0.50‐0.99, protective versus controls λ = 1.16‐2.23, progressor versus controls λ = 1.16‐2.50; representative quantile--quantile plots in Supporting Figs. [S1‐S3](#hep41227-sup-0002){ref-type="supplementary-material"}). Statistical significance was based on Bonferroni‐corrected thresholds for the number of variants or genes tested, respectively (Supporting Table [S1](#hep41227-sup-0001){ref-type="supplementary-material"}).

Results {#hep41227-sec-0006}
=======

Eighty‐two Caucasian NAFLD patients were included for analysis. Given the extreme phenotype design, all protective phenotype patients were age 50 or older with T2DM and obesity (median BMI = 41 kg/m^2^), whereas progressors were age 55 or younger without T2DM and lower median BMI (32 kg/m^2^). Most of the progressors were male and had a NAFLD activity score greater than or equal to 4 (Supporting Table [S2](#hep41227-sup-0001){ref-type="supplementary-material"}).

*NAFLD Progressor Versus* *NAFLD Protective* {#hep41227-sec-0007}
--------------------------------------------

No variants or genes reached genome‐wide statistical significance after quality control and multiple testing correction in the progressor versus protective extreme phenotypes comparison. However, there was nonsignificant enrichment of the known *PNPLA3*I148M (rs738409, *P*= 8.42E‐05) and *TM6SF2* E167K (rs58542926, *P*= 4.10E‐03) polymorphisms under single‐variant allelic models among the NAFLD progressors.[5](#hep41227-bib-0005){ref-type="ref"}, [6](#hep41227-bib-0006){ref-type="ref"}, [7](#hep41227-bib-0007){ref-type="ref"}, [8](#hep41227-bib-0008){ref-type="ref"}, [9](#hep41227-bib-0009){ref-type="ref"}, [11](#hep41227-bib-0011){ref-type="ref"} An adjacent synonymous variant in *PNPLA3*, P149 (rs738408, *P*= 8.42E‐05), in perfect linkage disequilibrium (r^2^ = 1) with I148M, also neared significance. *PNPLA3*I148M is in a common haplotype block and, although variants in nearby genes *PARVB* W37R and *SAMM50*G453 neared the genome‐wide significance threshold, adjustment for *PNPLA3*I148M completely eliminated any association signal in this region (data not shown), consistent with previous literature.[16](#hep41227-bib-0016){ref-type="ref"}

Among the top nonsignificant variants in our analysis, several were enriched in genes that differed between the NAFLD cohorts. These associations highlight genes and pathways that may either promote or protect against fibrosis progression; however, with current available evidence, their involvement remains uncertain. Nonsignificant variants enriched among progressors in biologically plausible, although not previously implicated, NAFLD genes included several immune‐related findings (Table [1](#hep41227-tbl-0001){ref-type="table"} and Supporting Tables [S3 and S4](#hep41227-sup-0001){ref-type="supplementary-material"}). Common variants with nonsignificant enrichment under allelic models included S31R (rs1801270, *P*= 1.30E‐03) in cyclin‐dependent kinase inhibitor 1A (*CDKN1A*) and L439V (rs11465927, *P*= 6.70E‐03) in interleukin 1 (IL1) receptor associated kinase 2 (*IRAK2)*. *CDKN1A* encodes p21, a senescence marker involved in innate immunity, whose hepatocyte expression has been associated with NAFLD fibrosis stage.[17](#hep41227-bib-0017){ref-type="ref"} A previous candidate gene study linked several *CDKN1A*variants with NAFLD fibrosis development, including S31R, although S31R was not associated with fibrosis and only borderline associated with steatohepatitis.[17](#hep41227-bib-0017){ref-type="ref"} IRAK2 is part of the innate immune response, acting in IL1R‐mediated and IL1‐mediated signaling. Under recessive models, I167V (rs1051061, *P*= 7.63E‐04) was enriched in vaccinia‐related kinase 2 (*VRK2*), an IL1‐mediated signaling effector.

###### 

NAFLD Progressor (N = 28) Versus Protective (N = 54) Comparison: Top Associated Variants in Biologically Relevant Genes

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       Variant   rs\#         NAFLD Progressors With Variant,\   NAFLD Protective With Variant,\   PolyPhen Prediction          ExAC Global MAF   Genetic Model   *P* Value   Enrichment
                                    N (MAF)                            N (MAF)                                                                                                      
  ---------- --------- ------------ ---------------------------------- --------------------------------- ---------------------------- ----------------- --------------- ----------- ------------
  *PNPLA3*   I148M     rs738409     24 (0.61)                          24 (0.28)                         Probably damaging            0.26              SV allelic      8.42E‐05    Progressor

  *PNPLA3*   P149      rs738408     24 (0.61)                          24 (0.28)                         NA                           0.26              SV allelic      8.42E‐05    Progressor

  *SAMM50*   G453      rs7587       1 (0.04)                           26 (0.27)                         NA                           0.22              SV allelic      4.23E‐04    Protective

  *PTX4*     G36C      rs1040499    11 (0.20)                          39 (0.47)                         Unknown                      0.41              SV allelic      6.26E‐04    Protective

  *PTX4*     R276K     rs2745098    12 (0.21)                          37 (0.46)                         Benign                       0.41              SV allelic      2.10E‐03    Protective

  *CDKN1A*   S31R      rs1801270    9 (0.18)                           3 (0.03)                          Benign                       0.15              SV allelic      1.30E‐03    Progressor

  *GBP1*     A409G     rs1048443    9 (0.16)                           36 (0.41)                         Probably/possibly damaging   0.30              SV allelic      1.40E‐03    Protective

  *TM6SF2*   E167K     rs58542926   5 (0.09)                           0 (0)                             Probably/possibly damaging   0.02              SV allelic      4.10E‐03    Progressor

  *IRAK2*    L439V     rs11465927   5 (0.11)                           1 (0.01)                          Benign                       0.03              SV allelic      6.70E‐03    Progressor

  *PARVB*    W37R      rs1007863    39 (0.44)                          39 (0.44)                         Benign                       0.44              SV recessive    2.28E‐04    Progressor

  *VRK2*     I167V     rs1051061    21 (0.57)                          36 (0.37)                         Probably damaging            0.36              SV recessive    7.63E‐04    Progressor

  *SEC31B*   L1071V    NA           1                                  0                                 Benign                       0                 GB dominant     0.006       Progressor

             V504M     rs41290542   6                                  3                                 Benign                       0.03                                          Progressor

             G86R      NA           1                                  0                                 Benign                       0                                             Progressor
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ExAC, exome aggregation consortium; GB, gene‐based; MAF, minor allele frequency; NA, not available; SV, single‐variant.

John Wiley & Sons, Ltd

Among the protective phenotype, in which variants might reduce fibrosis progression risk, several immune genes were among the top results, although not in the IL1 pathway. We saw nonsignificant enrichment in allelic models of G36C (rs1040499, *P*= 6.26E‐04) and R276K (rs2745098, *P*= 2.10E‐03) in long pentraxin 4 (*PTX4*), which are in high linkage disequilibrium (r^2^ = 0.93) as well as A409G (rs1048443, *P*= 1.40E‐03) in interferon (IFN)‐inducible guanylate binding protein 1 (*GBP1*). PTX4 is a potential functional antibody ancestor that acts in innate immunity, whereas GBP1 is a guanosine triphosphatase that regulates IL2 secretion and acts in cytokine, IFN‐γ, and T‐cell receptor--mediated signaling pathways.

*NAFLD Protective Versus* *Population Controls* {#hep41227-sec-0008}
-----------------------------------------------

The protective versus population control comparison investigated susceptibility to this NAFLD phenotype, as well as possible protective variants against advanced fibrosis. We did not discover any significant, high‐quality variants. Several nonsignificant rare variants in genes involved in immune‐, liver‐, lipid‐, or fibrosis‐related pathways were identified, although their NAFLD role remains unconfirmed (Table [2](#hep41227-tbl-0002){ref-type="table"} and Supporting Tables [S5 and S6](#hep41227-sup-0001){ref-type="supplementary-material"}).

###### 

NAFLD Protective (N = 54) Versus Population Controls (N = 4455) Comparison: Top Associated Variants in Biologically Relevant Genes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene        Variant        rs\#          NAFLD Protective With Variant,\   Controls With Variant,\   PolyPhen Prediction          ExAC Global MAF   Genetic Model   *P* Value
                                           N (MAF)                           N (MAF)                                                                                  
  ----------- -------------- ------------- --------------------------------- ------------------------- ---------------------------- ----------------- --------------- -----------
  *OIT3*      Y60            NA            2 (0.02)                          0 (0)                     NA                           0                 SV allelic      1.42E‐04

  *ABCA8*     P1396L         rs148226092   2 (0.02)                          0 (0)                     Probably damaging            8.68E‐05          SV allelic      1.42E‐04

  *SLAMF7*    I13V           NA            2 (0.02)                          0 (0)                     Benign                       7.15E‐05          SV allelic      1.42E‐04

  *PINK1*     L288           NA            2 (0.02)                          0 (0)                     NA                           3.95E‐05          SV allelic      1.42E‐04

  *PINK1*     P289T          NA            2 (0.02)                          0 (0)                     Probably damaging            3.95E‐05          SV allelic      1.42E‐04

  *IL32*      C161           NA            2 (0.02)                          0 (0)                     NA                           1.61E‐05          SV allelic      1.42E‐04

  *SMEK2*     T723A/ T808A   rs76512669    4 (0.04)                          20 (0.002)                Benign                       0.001             SV allelic      1.72E‐04

  *ORM1*      T151           NA            2 (0.02)                          1 (0.0001)                NA                           5.54E‐05          SV allelic      4.24E‐04

  *HNF1A*     P379A          NA            2 (0.02)                          1 (0.0001)                Probably damaging            2.10E‐04          SV allelic      4.30E‐04

  *PKD2L1*    L138\*         NA            1 (0.02)                          2 (0.0002)                NA                           1.90E‐04          SV allelic      8.39E‐04

  *IL6*       D162V          rs2069860     5                                 75                        Benign                       0.006             GB dominant     0.004

  *THEM5*     P246L          NA            1                                 0                         Benign                       8.00E‐06          GB dominant     0.006

              E168K          NA            1                                 0                         Probably/possibly damaging   2.00E‐04                          

  *CYP26B1*   V456L          NA            1                                 0                         Benign                       0                 GB recessive    0.012
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ExAC, exome aggregation consortium; GB, gene‐based; MAF, minor allele frequency; NA, not available; SV, single‐variant.

John Wiley & Sons, Ltd

Three extremely rare variants in immune‐related genes were nonsignficantly enriched among the NAFLD protective phenotype relative to population controls under single‐variant allelic models: I13V (*P*= 1.42E‐04) in SLAM (signaling lymphocytic activation molecule) family member 7 (*SLAMF7*), C161 (*P*= 1.42E‐04) in IL32*,*and T151 (*P*= 4.24E‐04) in orosomucoid 1 (*ORM1*). Under a dominant gene‐based model, D162V (rs2069860, *P*= 0.004) in IL6 was also enriched. IL6 influences inflammation‐associated disease states, including metabolic syndrome diseases such as diabetes. IL6 also upregulates IL32, which induces tumor necrosis factor‐α (TNF‐α) macrophage production and acts in oxidative damage response. Interestingly, IL32 can attenuate alcohol‐induced liver injury, as well as lipid accumulation in mice on a high‐fat diet.[18](#hep41227-bib-0018){ref-type="ref"}, [19](#hep41227-bib-0019){ref-type="ref"} Also within the IL6 pathway, ORM1 is an acute phase plasma reactant protein involved in immunosuppression, including negative regulation of IL6 and TNF‐α, with a potential role in alcoholic liver cirrhosis.[20](#hep41227-bib-0020){ref-type="ref"} SLAMF7 activates natural killer cells, inhibits pro‐inflammatory cytokines including TNF‐α, and has been associated with several autoimmune diseases including diabetes.[21](#hep41227-bib-0021){ref-type="ref"}

*NAFLD Progressor Versus* *Population Controls* {#hep41227-sec-0009}
-----------------------------------------------

In the progressor versus population control comparison, *PNPLA3* variants I148M and P149 reached statistical significance (both *P*= 2.10E‐09 allelic) despite small progressor sample size. Although there were no other robust, significant associations, we observed nonsignificant enrichment in several NAFLD‐associated genes: *TM6SF2* E167K (*P*= 8.88E‐04 allelic)*,* *PARVB,*and *SAMM50*. The enrichment of *PNPLA3*I148M and *TM6SF2* E167K in both the progressor versus protective and progressor versus control comparisons, but not in the protective versus control comparison, provides further evidence that these variants are important for NAFLD fibrosis progression independent of T2DM and obesity.

Among the top nonsignificant gene‐based associations, several genes were associated with metabolic syndrome and lipids (Table [3](#hep41227-tbl-0003){ref-type="table"} and Supporting Tables [S7 and S8](#hep41227-sup-0001){ref-type="supplementary-material"}). Under a dominant gene‐based model, we observed nonsignificant enrichment of rare variation in the major histocompatibility complex I immune response molecule alpha‐2‐glycoprotein 1 zinc‐binding (*AZGP1*; *P*= 0.007, H214Q and A46V), which regulates fatty acid synthesis and cell adhesion. AZGP1 is implicated in metabolic syndrome and insulin sensitivity, is elevated in kidney injury, and is a lipid catabolism biomarker. Additionally, under recessive single‐variant and gene‐based models, a single nonsynonymous variant, I717V (rs2759, *P*= 7.76E‐04 single‐variant; *P*= 7.75E‐04 gene‐based) was enriched in myeloperoxidase (*MPO*), a major component of neutrophil granules that acts in low‐density lipoprotein remodeling.[22](#hep41227-bib-0022){ref-type="ref"} *MPO* has been linked to various metabolic syndrome diseases and is involved in stimuli responses including to food and lipopolysaccharides.[22](#hep41227-bib-0022){ref-type="ref"} Further, a *MPO* promoter polymorphism (−463G \> A) was previously implicated in fibrosis severity in women with hepatitis C,[23](#hep41227-bib-0023){ref-type="ref"} consistent with its enrichment among advanced fibrosis observed here. *MPO*was also enriched among progressors in the gene‐based recessive model for the progressor versus protective analysis, potentially implying a role in advanced fibrosis, if confirmed.

###### 

NAFLD Progressor (N = 28) Versus Population Controls (N = 4455) Comparison: Top Associated Variants in Biologically Relevant Genes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene          Variant                    rs\#                       NAFLD Progressors With Variant,\   Controls With Variant,\   PolyPhen Prediction               ExAC Global MAF      Genetic Model                  *P* Value
                                                                      N (MAF)                            N (MAF)                                                                                                         
  ------------- -------------------------- -------------------------- ---------------------------------- ------------------------- --------------------------------- -------------------- ------------------------------ ----------------
  *PNPLA3*      *P149*                     *rs738408*                 *24 (0.61)*                        *1826 (0.23)*             *NA*                              *0.26*               *SV allelic (and recessive)*   ***2.09E‐09***

  *PNPLA3*      *I148M*                    *rs738409*                 *24 (0.61)*                        *1826 (0.23)*             *Probably damaging*               *0.26*               *SV allelic (and recessive)*   ***2.10E‐09***

  *PARVB*       W37R                       rs1007863                  23 (0.70)                          2691 (0.40)               Benign                            0.44                 SV allelic (and recessive)     8.20E‐06

  *SAMM50*      D110G                      rs3761472                  17 (0.38)                          1329 (0.16)               Benign                            0.21                 SV allelic                     1.45E‐04

  *TM6SF2*      E167K                      rs58542926                 9 (0.20)                           549 (0.06)                Probably/possibly damaging        0.07                 SV allelic                     8.88E‐04

  *MPO*         I717V                      rs2759                     4 (0.11)                           237 (0.03)                Benign                            0.02                 SV recessive                   7.76E‐04

  *HIST1H2BC*   FS (chr6: 26124019 insT)   NA                         1                                  1                         NA                                0                    GB dominant                    0.002

                A22S                       NA                         1                                  1                         Unknown                           2.00E‐05                                            

  *AZGP1*       H214Q                      NA                         1                                  1                         Benign                            2.00E‐05             GB dominant                    0.007

                A46V                       rs142669146                1                                  0                         Benign                            1.00E‐04                                            

  *MRGPRX1*     Q307R                      rs138752944                1                                  0                         Benign                            3.00E‐04             GB recessive                   7.75E‐04

                Q307\*                     rs140371088                1                                  0                         NA                                3.00E‐04                                            

                Y272C                      NA                         1                                  0                         Probably damaging                 1.00E‐04                                            

  *CYP26B1*     A420G and R191H            rs7568553 and rs76025186   1                                  0                         Benign and probably damaging      0.005 and 0.001      GB compound‐heterozygous       0.006

  *EFCAB13*     K244\* and T577R/T481R     NA and rs142664574         1                                  0                         NA and possibly damaging/benign   2.00E‐05 and 0.005   GB compound‐heterozygous       0.007
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: Italicized and bolded variants reached statistical significance.

Abbreviations: ExAC, exome aggregation consortium; GB, gene‐based; MAF, minor allele frequency; NA, not available; SV, single‐variant

John Wiley & Sons, Ltd

Discussion {#hep41227-sec-0010}
==========

A major goal in caring for patients with NAFLD is determining who is at risk for fibrosis and thus poor outcomes. We aimed to determine the contribution of genetic variants to this risk by using WES in patients at NAFLD extremes. We confirmed the significance of *PNPLA3* I148M in NAFLD fibrosis progression as identified in previous studies.[8](#hep41227-bib-0008){ref-type="ref"}, [9](#hep41227-bib-0009){ref-type="ref"} Importantly, we were able to do this in a small NAFLD cohort through accurate phenotyping of biopsy‐proven NAFLD patients. Our results support a role for *PNPLA3*directly in NAFLD fibrosis severity, as previously implicated,[7](#hep41227-bib-0007){ref-type="ref"} and the recent suggestion that *PNPLA3* potentiates the pro‐fibrogenic features of hepatic stellate cells.[24](#hep41227-bib-0024){ref-type="ref"} Similarly, the enrichment of *TM6SF2* E167K observed among progressors is consistent with previous associations between E167K and hepatic fibrosis progression in NAFLD,[11](#hep41227-bib-0011){ref-type="ref"} although it did not reach significance in this study.

Although only *PNPLA3* reached statistical significance, and only in the larger progressor versus control comparison, we observed several suggestive associations in biologically relevant genes broadly in line with a role for a pro‐inflammatory state in NAFLD development. These findings are important for future hypothesis‐driven research but require replication in independent NAFLD cohorts, as immune genes compose a substantial fraction of the human genome, enabling considerable narrative potential. Among the top associations in the NAFLD progressor versus protective comparison, several affected the immune genes, with distinct genes and biological processes observed for each phenotype. Among progressors, two variants were enriched in IL1 signaling pathway genes (*IRAK2*and *VRK2*), which could conceivably reflect disruption of this innate immune and tissue regeneration pathway in advanced fibrosis progression.[25](#hep41227-bib-0025){ref-type="ref"}

In contrast, several variants enriched among high‐risk, low‐fibrotic NAFLD patients were observed in IL6‐related genes (*IL6*, *IL32*, *ORM1,*and *SLAMF7*) in the NAFLD susceptibility investigation of protective versus population controls, suggesting a potential role for a pro‐inflammatory immune response. This finding is supported by recently published NASH Clinical Research Network data implicating pro‐inflammatory pathways, including common variants in *IL1B* and *IL6*, with NAFLD fibrosis risk and ballooning.[25](#hep41227-bib-0025){ref-type="ref"} However, as protective individuals were obese with T2DM as part of the study design, the IL6‐related genes may also reflect T2DM risk.

Our findings are important for several reasons. First, we used gold standard liver biopsy--confirmed NAFLD to ensure accurate histologic phenotyping of patients. Second, we report the first WES investigation of genetic variation in NAFLD fibrosis. Third, the extreme phenotype design assisted in overcoming difficulties of accurate phenotyping in a highly heterogeneous disease such as NAFLD. This has been a major challenge for GWAS, as variable clinical factors contribute to diverse molecular pathogenesis even with similar histologic phenotypes. We selected extreme phenotypes to control clinical factors associated with risk or protection from advanced fibrosis including obesity, age, and T2DM. Due to the feasibility of having sufficient specimen availability meeting criteria, the histologic extremes could not be completely separated. This may have reduced our ability to detect fibrosis‐associated variants specific to NASH and represents a study limitation. Additionally, as most patients had stages 0, 1, and 3 fibrosis, it was not possible to identify extremes with just isolated steatosis or cirrhosis. Although we included population controls from studies unrelated to viral hepatitis or liver disease to increase power and generalizability, detailed phenotyping information about NAFLD and risk factors, such as obesity and diabetes, was unavailable. As NAFLD is relatively common in the general population,[1](#hep41227-bib-0001){ref-type="ref"} another limitation is the potential for misclassification among controls, leaving our results conservative. Indeed, we did not observe any association with *HSD17B13,*likely due to a combination of sample‐size constraints and differences in investigated phenotypes, as our study focused on histological fibrosis, whereas *HSD17B13* initially associated with serum alanine and aspartate aminotransferases.[10](#hep41227-bib-0010){ref-type="ref"} Finally, as individuals with the protective phenotype were older, obese and diabetic, the protective phenotype comparison with population controls may have reflected an underlying genetic risk for NAFLD or diabetes susceptibility, whereas the progressor versus control comparison uniquely interrogated risks for advanced fibrosis among NAFLD patients without diabetes.

Although many of our results were not significant, we hope that this investigation will pave the way for further next‐generation‐sequencing studies. We have highlighted several biologically plausible genes among our top associations, although we currently lack the evidence necessary to determine their NAFLD fibrosis involvement. However, if confirmed in future studies, they may warrant further investigation in the search for pathogenic and therapeutic targets in NASH and liver fibrosis. This study suggests that "extreme" NAFLD phenotypes may represent distinct disease subtypes, perhaps accounting for the nonlinear nature of fibrosis progression. Improved delineation of these subtypes and genetic risks will require large, well‐phenotyped follow‐up studies. Ideally, the goal is to develop personalized variant profiles for NAFLD based on the risk of progression to fibrosis and fatal liver outcomes, enabling not only personalized treatment options for NAFLD but early identification and prevention of this extremely common disease.
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